FEBRUARY 9, 2007 - A survey conducted by Directive Analytics for Siemens Medical Solutions indicates that nearly 72 percent of consumers would opt for a test that identifies diseases 20 years before symptoms appear. The survey also found that 35 percent want to know if they would be diagnosed with an incurable disease during their lifetime.

The survey consisted of a national online poll of 1,111 adults and was conducted to assess consumer attitudes toward growing scientific capabilities to predict diseases and disease onset.

The survey also uncovered: 52 percent of Americans would take necessary actions - despite the cost - to find treatment if they were diagnosed with an incurable disease; women would be more proactive with such actions than men; consumer knowledge of medical equipment is lacking; and middle-aged and affluent consumers are most curious about their future health, including diseases for which there are no current cures.


Related Content

Feature | Radiology Business | By Melinda Taschetta-Millane

Here is what you and your colleagues found to be most interesting in the field of medical imaging during the month of ...

Time August 01, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

February 24, 2021 — Frost & Sullivan's recent analysis, Technological Advancements and Emerging Applications in the ...

Time February 24, 2021
arrow
Technology | Fusion Imaging Software

MIM Software Inc. announced in November the commercial introduction of its MRI (magnetic resonance imaging) Prostate Fusion Software as a fully integrated software on BK Ultrasound’s premium bk3000 ultrasound system. The global launch of this solution for prostate biopsy, bkFusion, was developed in partnership between the companies.

Time January 03, 2017
arrow
Videos | RSNA 2016

ITN and DAIC Editor Dave Fornell takes a tour of some of the most innovative new technologies being displayed on the ...

Time December 19, 2016
arrow
Technology | Fusion Imaging Software

February 16, 2016 — Clear Guide Medical has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) ...

Time February 16, 2016
arrow
Technology

Esaote North America received U.S. Food and Drug Administration (FDA) clearance to market and sell its Virtual Navigator fusion imaging technology for ultrasound to U.S. customers.

Time May 13, 2014
arrow
Technology

Aycan and Chimaera GmbH received U.S. Food and Drug Administration (FDA) 510(k) clearance of Chimaera FusionSync, a software tool for more efficient handling and diagnosis of multi-modal and follow-up medical data. Available with Aycan workstation OsiriX Pro, Chimaera FusionSync was launched in Europe in 2013 with CE marking.

Time March 04, 2014
arrow
Technology

Blackford Analysis, a provider of software products that accelerate comparison of medical images, announced it will launch its complete product range at the 2013 Radiological Society of North America Scientific Assembly and Annual Meeting (RSNA 2013) in Chicago.

Time November 07, 2013
arrow
Technology

Aspect Imaging launched LumiQuant, its software and hardware solution for co-registering and measuring luminescence imaging images with the Bruker Icon compact high-performance magnetic resonance imaging (MRI) system. The LumiQuant solution enables researchers to generate 3-D luminescence data co-registered with MRI, a path forward in multi-modal tomographic imaging.

Time April 12, 2013
arrow
Technology

November 30, 2011 — Toshiba America Medical Systems Inc., launched the Aplio 500 ultrasound system, enabling clinicians to diagnose using advanced visualization tools. The system is 510(k) cleared by the U.S. Food and Drug Administration (FDA) and displayed at the Radiological Society of North America (RSNA) annual meeting in Chicago, Nov. 27 – Dec. 2.

Time November 30, 2011
arrow
Subscribe Now